SS-31, also known as Elamipretide, Bendavia, or MTP-131, is a synthetic aromatic-cationic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH2. Developed by Stealth BioTherapeutics, it was designed specifically to target mitochondrial membranes, where it concentrates at levels 1,000 to 5,000 times higher than the surrounding cytosol. Unlike traditional antioxidants that neutralize reactive oxygen species after they are generated, SS-31 works upstream by protecting the structural integrity of cardiolipin — a critical phospholipid embedded in the inner mitochondrial membrane.
Primary areas of research include:
- Cardiac protection during ischemia-reperfusion injury
- Heart failure with reduced ejection fraction
- Barth syndrome and primary mitochondrial myopathy
- Age-related mitochondrial decline and skeletal muscle atrophy
- Renal protection and neuroprotection in preclinical models
What Is SS-31?
SS-31 (Elamipretide) is a first-in-class mitochondria-targeting peptide developed to address the root cause of diseases driven by mitochondrial dysfunction. It is a tetrapeptide — a chain of just four amino acids — with a unique structure that allows it to selectively accumulate within mitochondria rather than distributing broadly throughout the cell.
The compound was created with a specific molecular rationale: cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane, plays a structural role in organizing the electron transport chain complexes that generate ATP. In aging, disease, and ischemic injury, cardiolipin becomes oxidized and peroxidized, destabilizing these complexes and impairing energy production. SS-31 binds to cardiolipin through electrostatic and hydrophobic interactions, preventing its oxidation and preserving the architecture of the electron transport chain.
This mechanism distinguishes SS-31 from both conventional antioxidants (which scavenge free radicals after they are produced) and most peptides in the biohacking space (which act through growth factor or hormonal pathways). SS-31 operates at the level of cellular bioenergetics, making it particularly relevant for conditions where mitochondrial failure is a primary driver of pathology.
How It Works
Cardiolipin Stabilization
The central mechanism of SS-31 is its interaction with cardiolipin in the inner mitochondrial membrane. Cardiolipin serves as a scaffold for the protein complexes of the electron transport chain (Complexes I, III, and IV), holding them in the optimal spatial arrangement for efficient electron transfer. When cardiolipin is damaged by reactive oxygen species, these complexes dissociate and electron transfer becomes inefficient — generating more reactive oxygen species in a destructive feedback loop.
SS-31 binds cardiolipin through a combination of electrostatic attraction (its cationic charge is drawn to cardiolipin's anionic head groups) and hydrophobic insertion (its aromatic residues embed in the lipid bilayer). This stabilization prevents cardiolipin peroxidation and maintains the structural integrity of the electron transport chain.
Electron Transport Chain Optimization
By preserving cardiolipin and the supramolecular organization of electron transport chain complexes, SS-31 optimizes electron flow through Complexes I, III, and IV. This improved electron transfer efficiency has two consequences: increased ATP production and reduced superoxide radical generation. In dysfunctional mitochondria, studies have demonstrated that SS-31 can improve ATP production by 30–60%, while simultaneously reducing harmful reactive oxygen species that would otherwise damage cellular components.
Mitochondrial Dynamics and Biogenesis
Evidence from preclinical studies suggests SS-31 also activates PGC-1α signaling pathways, a master regulator of mitochondrial biogenesis. Activation of this pathway promotes mitochondrial fusion and the generation of new mitochondria, contributing to improvements in overall mitochondrial mass and function over extended treatment periods. This biogenesis effect may explain why some structural and functional benefits continue to develop over months of treatment.
Anti-Inflammatory Effects
Mitochondrial reactive oxygen species are potent activators of the NLRP3 inflammasome, a multiprotein complex that drives inflammatory cytokine production. By reducing mitochondrial reactive oxygen species generation, SS-31 reduces NLRP3 inflammasome activation and the subsequent release of pro-inflammatory cytokines including IL-1β and IL-18. This anti-inflammatory effect has been observed across multiple tissue types in preclinical research and may contribute to the compound's protective effects in cardiac and renal injury models.
Dosage Protocols
No FDA-approved dosing guidelines exist for SS-31 outside of clinical trial protocols. The following dosing information is derived from published clinical research and community reports:
Clinical Trial Dosing:
- EMBRACE-STEMI trial: Intravenous infusion of 0.05 mg/kg/hour over 1 hour
- PROGRESS-HF trial: Single 4-hour intravenous infusion at 0.005, 0.05, or 0.25 mg/kg/hour
- Primary mitochondrial myopathy trials (MMPOWER-3): 40 mg/day subcutaneously for up to 24 weeks
- TAZPOWER trial (Barth syndrome): 40 mg/day subcutaneously for 28 weeks
Community and Research Chemical Use:
- Conservative starting dose: 5 mg subcutaneously once daily
- Moderate dose: 10–20 mg subcutaneously once daily
- Higher dose: 20–40 mg subcutaneously once daily (matching clinical trial dosing for mitochondrial myopathy)
These doses reflect clinical trial protocols for specific conditions (primary mitochondrial myopathy, Barth syndrome). No published data exists for subcutaneous self-administration in healthy individuals. Note: the Phase 3 MMPOWER-3 trial did not meet its primary endpoints for the general PMM population.
Cycling Guidelines:
- Clinical trials used continuous dosing for up to 36 weeks without apparent tolerance
- Community protocols sometimes implement 8 weeks on, 4 weeks off
- Cycling scientific necessity is unestablished; continuous use mirrors clinical trial practice
- Morning administration may align better with circadian rhythms governing mitochondrial activity
How to Use / Administration Methods
Subcutaneous Injection (Most Common): The standard route for both clinical and community use. Lyophilized powder is reconstituted with bacteriostatic water to a concentration of 5–10 mg/mL and administered using an insulin syringe into the abdominal area with rotating injection sites. Subcutaneous injection provides reliable absorption with minimal procedural complexity.
Intravenous Infusion (Clinical Setting Only): Used in cardiac trials such as EMBRACE-STEMI, IV administration requires clinical supervision and is not appropriate for self-administration. The pharmacokinetic profile differs from subcutaneous dosing and is not directly translatable to community protocols.
Oral Administration: Oral bioavailability is significantly reduced compared to injection due to peptide degradation in the gastrointestinal tract. Oral formulations have been explored but subcutaneous injection remains the preferred route for meaningful systemic exposure.
Reconstitution: Add bacteriostatic water slowly along the interior vial wall — do not inject directly onto the powder under pressure. Gently swirl to dissolve; do not shake vigorously. Allow several minutes for complete dissolution.
Results Timelines
Hours to Days:
- Acute improvements in exercise tolerance and reduced fatigue
- Enhanced post-exercise recovery
- Initial reductions in oxidative stress markers
Weeks 1–4:
- Measurable improvements in cardiac function parameters
- Increases in exercise capacity (e.g., 6-minute walk distance)
- Changes in circulating oxidative stress biomarkers
- Subjective improvements in energy and cognitive clarity reported anecdotally
Weeks 4–12+:
- Structural mitochondrial improvements including enhanced biogenesis
- Progressive gains in tissue function across cardiac, renal, and skeletal muscle systems
- Continued functional capacity improvements in disease populations
The distinction between acute (hours) and structural (months) benefits reflects two separate mechanisms: immediate cardiolipin stabilization affecting current mitochondrial efficiency, and longer-term biogenesis effects requiring PGC-1α-driven mitochondrial synthesis.
Research Evidence
SS-31 has accumulated a clinical trial dataset that, while modest in size, is substantially more robust than most peptides currently in use within the biohacking community.
EMBRACE-STEMI Trial
The EMBRACE-STEMI (Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With AMI) Phase 2a trial enrolled patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction. A single intravenous infusion of 0.05 mg/kg was administered before reperfusion. The primary endpoint of infarct size reduction was not met in the overall population, but subgroup analyses suggested potential benefits in patients with anterior infarctions — a higher-risk subgroup with greater myocardial mass at risk.
PROGRESS-HF Trial
The PROGRESS-HF trial examined elamipretide in patients with heart failure with reduced ejection fraction. The trial demonstrated improvement in left ventricular end-systolic volume with trends toward improved cardiac function, though primary endpoints were not achieved. The mechanistic rationale — that chronic heart failure involves progressive mitochondrial dysfunction — remains scientifically sound and continues to motivate further research in this indication.
Barth Syndrome — TAZPOWER Trial
Barth syndrome is a rare X-linked mitochondrial disease caused by mutations in the tafazzin gene, resulting in abnormal cardiolipin composition. The TAZPOWER trial evaluated elamipretide in patients with Barth syndrome and demonstrated clinically meaningful improvements in 6-minute walk distance and cardiac function. This represents the most positive clinical trial result for SS-31 and provided the basis for its Rare Pediatric Disease and Orphan Drug designations.
Primary Mitochondrial Myopathy
A randomized dose-escalation trial published in Neurology (Karaa et al., 2018) examined elamipretide in adults with primary mitochondrial myopathy. The trial showed improvements in functional capacity measures and was well-tolerated across the dose range studied, providing safety and preliminary efficacy data in a mitochondrial disease population.
Preclinical Evidence
Preclinical research in rodent and canine models has demonstrated protective effects of SS-31 across multiple systems:
- Cardiac: Protection against age-related diastolic dysfunction; preserved systolic function in canine heart failure models
- Renal: Reduced injury from ischemia-reperfusion in acute kidney injury models
- Skeletal muscle: Attenuation of age-related sarcopenia and disuse atrophy
- Neurological: Protection against mitochondrial dysfunction in neurodegeneration models
The preclinical dataset across these systems is extensive and mechanistically coherent, providing a strong rationale for continued clinical investigation.
Stacking
SS-31's mitochondria-specific mechanism is genuinely complementary to several other compounds targeting cellular energy systems. Unlike many peptide stacking combinations that lack mechanistic rationale, combinations with mitochondrial support compounds have scientific logic.
SS-31 + NAD+ Precursors (NMN or NR)
Potentially the most synergistic combination. NAD+ is an essential cofactor for electron transport chain function and a substrate for sirtuins (mitochondrial quality control enzymes). SS-31 optimizes the structural efficiency of the electron transport chain; NAD+ precursors increase the availability of the key electron carrier. Together, they address both the structural and substrate limitations of aging mitochondria.
SS-31 + CoQ10 / Ubiquinol
Coenzyme Q10 functions as an electron carrier between Complexes I/II and Complex III in the electron transport chain. SS-31 stabilizes the protein complexes through which CoQ10 shuttles electrons. These mechanisms are genuinely complementary, with CoQ10 addressing electron carrier availability while SS-31 preserves the structural context in which CoQ10 operates.
SS-31 + PQQ (Pyrroloquinoline Quinone)
PQQ promotes mitochondrial biogenesis through activation of PGC-1α signaling. SS-31 also appears to activate PGC-1α. Their combination may produce additive or synergistic biogenesis stimulation, though direct evidence is lacking.
SS-31 + BPC-157
For tissue healing applications, particularly in post-injury recovery or surgical contexts where both mitochondrial function and tissue repair are priorities. BPC-157 supports angiogenesis and structural repair while SS-31 addresses the cellular energy deficits that accompany tissue injury. No formal research examines this combination.
General Stacking Caution: Formal drug interaction studies are absent for all SS-31 combinations. Establishing individual response to SS-31 alone before adding additional compounds allows clearer attribution of effects and identification of tolerability issues.
Reconstitution, Storage & Prep
SS-31 is supplied as a lyophilized (freeze-dried) powder requiring reconstitution before subcutaneous injection.
Reconstitution Process:
- Allow vial to reach room temperature before opening
- Use bacteriostatic water (0.9% benzyl alcohol) as the reconstitution vehicle
- Draw the appropriate volume of bacteriostatic water into an insulin syringe
- Insert the needle into the vial and inject the water slowly along the interior vial wall — do not jet the water directly onto the powder
- Do not shake — gently swirl until the powder is fully dissolved (typically several minutes)
- Inspect the solution; it should be clear and colorless
Common Reconstitution Ratios:
- 40 mg SS-31 + 4 mL bacteriostatic water = 10 mg/mL (20 mg per 0.2 mL / 20 units on insulin syringe)
- 40 mg SS-31 + 8 mL bacteriostatic water = 5 mg/mL (20 mg per 0.4 mL / 40 units on insulin syringe)
Storage Guidelines:
- Lyophilized (unreconstituted): Store at -20°C for long-term; stable at 2–8°C for several months
- Protect from light and moisture at all times
- Reconstituted solution: Store at 2–8°C (refrigerator); use within 28 days
- Discard if solution becomes cloudy, discolored, or contains particulate matter
- Single-use vials reconstituted with non-preserved sterile water should not be stored
Side Effects
Published clinical trials present a favorable safety profile, with most adverse events being mild and consistent with placebo rates for serious events.
Commonly Reported:
- Injection site reactions including redness, mild swelling, and localized pain
- Headache (reported at slightly higher rates than placebo in some trials)
- Nausea (typically mild and transient)
Less Commonly Reported:
- Dizziness
- Fatigue (distinct from the underlying condition being treated)
- Gastrointestinal discomfort (typically resolving without intervention)
Serious Adverse Events: No serious adverse events have been definitively attributed to SS-31 in published clinical trials. Theoretical concerns about downstream cellular signaling effects from broad mitochondrial optimization exist but have not materialized as clinical toxicity signals in trials to date. No carcinogenicity evidence has emerged in preclinical research.
Sourcing Risks: Individuals sourcing SS-31 from unregulated research chemical suppliers face contamination and purity risks that are separate from the compound's intrinsic safety profile. Quality and purity cannot be verified without independent third-party testing.
Legal Status / FDA
SS-31 (Elamipretide) remains an investigational new drug without FDA approval for any clinical indication. Its regulatory pathway has been substantially supported by designation programs:
- Fast Track Designation: Granted for Barth syndrome and primary mitochondrial myopathy, enabling more frequent FDA interaction during development
- Orphan Drug Designation: Granted for Barth syndrome, providing market exclusivity and development incentives
- Rare Pediatric Disease Designation: Granted for Barth syndrome, enabling Priority Review Voucher eligibility upon approval
Key Regulatory Points:
- Not FDA-approved for any medical indication
- Cannot legally be sold as a drug, food, or dietary supplement intended for human consumption
- Exists in a regulatory gray area as a research chemical when sold without therapeutic claims
- Not DEA-scheduled; possession for personal research typically escapes enforcement
- International regulations vary significantly — status in Australia, Canada, UK, and EU differs from the U.S. framework
Stealth BioTherapeutics, the developer, has continued elamipretide development through multiple Phase 2 trials. The compound's clinical progression distinguishes it from many biohacking-community peptides that have no formal clinical development history.
Sports / WADA
SS-31 is not currently listed on the World Anti-Doping Agency Prohibited List. Unlike BPC-157, which received an explicit WADA ban in 2022, SS-31 has not been specifically addressed in current anti-doping frameworks.
However, athletes subject to anti-doping regulations should exercise caution:
- WADA's S0 category prohibits "non-approved substances" that are pharmacological agents not approved by any regulatory authority for human use, if used for performance enhancement
- SS-31's potential to improve exercise capacity, mitochondrial efficiency, and recovery could attract future regulatory scrutiny
- Individual sports organizations may have broader prohibitions covering investigational drugs
- Athletes in high-consequence sports should seek guidance from their relevant anti-doping authority before use
The absence of a current explicit ban does not guarantee future status or protection from non-specific prohibitions in individual sports federations.
Conclusion
SS-31 (Elamipretide) occupies a unique position among peptides being explored in the longevity and performance communities: it has a well-characterized molecular mechanism, a coherent scientific rationale, and an actual clinical trial record spanning rare diseases and cardiovascular conditions. This distinguishes it meaningfully from compounds whose use rests entirely on preclinical animal data or anecdotal reports.
The clinical evidence to date is mixed — primary endpoints in the largest cardiac trials were not met — but the mechanistic foundation remains compelling, subgroup analyses have suggested benefit in specific populations, and the Barth syndrome data represents a genuine clinical signal in a disease driven by the same cardiolipin dysfunction SS-31 is designed to address.
For individuals using SS-31 outside clinical trials, the critical limitations are sourcing quality, the absence of approved dosing protocols for healthy populations, and the limited long-term safety data in non-diseased subjects. The compound's favorable trial safety profile is encouraging, but it was generated in monitored clinical settings with pharmaceutical-grade material — not research chemical procurement chains.
SS-31 represents one of the most scientifically grounded compounds in the mitochondrial health space. Its mechanism is specific, its preclinical evidence is broad, and its clinical program is ongoing. The appropriate disposition toward it is informed optimism combined with realistic acknowledgment of what remains unproven in the healthy human context.